X0305 4/A 2012-05-14 2012-05-16 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001294596 Wysenski Nancy C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2012-05-14 4 S 0 179628 64.27 D 32604 D Common Stock 2012-05-14 4 S 0 372 65.00 D 32232 D Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82). Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. David T. Howton, Attorney-In-Fact 2012-06-01